Ventyx's clinical pipeline includes multiple small molecules with potential for oral therapies addressing chronic inflammation Acquisition builds on ...

The nonapeptide Oxytocin is a cyclic nine-amino‐acid peptide that has long been studied for its possible roles in ...

Kallyope, a late-stage biotechnology company focused on developing innovative migraine and metabolic disease therapies for health challenges faced by hundreds of millions of people globally, announced ...

Longevity has officially entered its evidence-backed era. What was once the domain of biohackers and academic labs is now a ...

CARDINAL Phase 1/2 trial of TERN-701 enrolling well, with multiple important milestones in 2026Planned milestones include pivotal dose selection, ...

Jefferies, TD Cowen and Piper Sandler are acting as joint book-running managers for the offering. Wedbush PacGrow and LifeSci Capital are acting as passive bookrunners for this offering.

Fungal infections kill millions of people each year, and modern medicine is struggling to keep up. But researchers at ...

When inflammation in the body goes unchecked, it can cause fibrosis, or tissue scarring that may lead to organ dysfunction or ...

Trading below net cash holdings ahead of that deal, the business faced a challenging outlook. This made it so that I erred on ...

The deal brings Dark Blue's preclinical oncology products, including an MLLT1/3-targeted agent for leukemias, into Amgen's portfolio.

Researchers at Case Western Reserve University have developed a treatment for advanced prostate cancer that could eliminate a ...

Partnership addresses the unmet need for remyelination therapies for multiple sclerosis and other demyelinating conditions by ...